Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase NCT03031782 (CAIN457F2304) Psoriatic arthritis Phase 3 Patients 80 Primary Outcome Measures Time to 33 flares Arms Intervention Secukinumab (pre-filled syringe) 75 mg Placebo Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis Target Patients Read-out Milesstone(s) H1-2021 Publication H2-2021 NCT03259074 SURPASS (CAIN457K2340) Ankylosing spondylitis Phase 3 837 No radiographic structural progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Secukinumab 150/300 mg Adalimumab biosimilar 40 mg Patients with active ankylosing spondylitis 2022 Study design manuscript published. Baraliakos et al. Clinical Drug Investigation (2020) 40:269-278. 73 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation